BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 12735212)

  • 1. Erythropoietin and chronic lymphocytic leukemia.
    Mauro FR; Gentile M; Foa R
    Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anemia in chronic lymphatic leukemia: is erythropoietin the solution?].
    de Gaona ER; Rifón J; Pérez-Calvo J; Bendandi M; Iglesias R; Panizo C
    Rev Med Univ Navarra; 2007; 51(1):3-10. PubMed ID: 17555114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-related anemia in chronic lymphocytic leukemia is not due to intrinsic defects of erythroid precursors: a possible pathogenetic role for tumor necrosis factor-alpha.
    Tsopra OA; Ziros PG; Lagadinou ED; Symeonidis A; Kouraklis-Symeonidis A; Thanopoulou E; Angelopoulou MK; Vassilakopoulos TP; Pangalis GA; Zoumbos NC
    Acta Haematol; 2009; 121(4):187-95. PubMed ID: 19468203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recombinant human erythropoietin in the treatment of anemia associated with lymphoproliferative diseases--chronic lymphadenosis and multiple myeloma].
    Haber J; Spicka I; Petruzelka L; Kolesková E; Straub J; Jonásová A; Pospísilová B
    Vnitr Lek; 1996 Apr; 42(4):262-7. PubMed ID: 8693713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia.
    Diehl LF; Ketchum LH
    Semin Oncol; 1998 Feb; 25(1):80-97. PubMed ID: 9482530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
    Henry DH; Abels RI
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anemia in multiple myeloma.
    Ludwig H; Pohl G; Osterborg A
    Clin Adv Hematol Oncol; 2004 Apr; 2(4):233-41. PubMed ID: 16163188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of anaemia in patients with malignancy: implications for the clinical use of recombinant human erythropoietin.
    Cazzola M
    Med Oncol; 2000 Nov; 17 Suppl 1():S11-6. PubMed ID: 11188780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer.
    Beguin Y
    Med Oncol; 1998 Aug; 15 Suppl 1():S38-46. PubMed ID: 9785336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.
    Desai J; Demetri GD
    Best Pract Res Clin Haematol; 2005; 18(3):389-406. PubMed ID: 15792913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to recombinant human erythropoietin causing pure red cell aplasia.
    Prabhakar SS; Muhlfelder T
    Clin Nephrol; 1997 May; 47(5):331-5. PubMed ID: 9181281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responsiveness to recombinant human erythropoietin (rh-Epo) of marrow erythroid progenitors (CFU-E and BFU-E) from B-chronic lymphocytic leukemia (B-CLL).
    Tsatalas C; Chalkia P; Tsantali C; Kakoulidis I; Garyfallos A; Klonizakis I; Panayiotopoulos S
    J Exp Clin Cancer Res; 1997 Jun; 16(2):163-70. PubMed ID: 9261742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EPO in cancer anemia: benefits and potential risks.
    Milano M; Schneider M
    Crit Rev Oncol Hematol; 2007 May; 62(2):119-25. PubMed ID: 17197190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies.
    Mittelman M; Zeidman A; Kanter P; Katz O; Oster H; Rund D; Neumann D
    Eur J Haematol; 2004 Mar; 72(3):155-65. PubMed ID: 14962233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The use of erythropoietin alpha in programs of high-dose chemotherapy].
    Danova M; Aglietta M; Pierelli L; Ferrari S; Perillo A; Scambia G; Henry D
    Recenti Prog Med; 2000 Dec; 91(12):681-9. PubMed ID: 11194490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pure red cell aplasia in patients treated with recombinant erythropoietin for anemia due to chronic renal disease].
    Miyazaki T; Obana T; Takasaki H; Tanaka M; Yamaji S; Fujimaki K; Fujita H; Kanamori H; Ishigatsubo Y
    Rinsho Ketsueki; 2007 May; 48(5):391-6. PubMed ID: 17571584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.
    Henry DH; Brooks BJ; Case DC; Fishkin E; Jacobson R; Keller AM; Kugler J; Moore J; Silver RT; Storniolo AM; Abels RI; Gordon DS; Nelson R; Larholt K; Bryant E; Rudnick S
    Cancer J Sci Am; 1995; 1(4):252-60. PubMed ID: 9166485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis.
    Kaltwasser JP; Kessler U; Gottschalk R; Stucki G; Möller B
    J Rheumatol; 2001 Nov; 28(11):2430-6. PubMed ID: 11708414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.